IL17A and type 1 diabetes mellitus: Moreover, inhibition of Th17 cells with neutralising anti-IL-17 antibodies or with recombinant IL-25 prevents diabetes in NOD mice when treatment is started at 10 weeks but not 5 weeks of age [53], illustrating the importance of this cell population in the pathogenesis of T1D as well as the role of different time windows required for T1D preventive interventions.